home > research channels > sectors > pharma > reports

Reports Archive   Year   
Date Title Pages Source Download
Nov-18 Performance in-line but outlook tepid   16 Edelweiss Securities
Oct-18 US generics – on a marginal recovery path   16 Motilal Oswal
Oct-18 2QFY19 Results Preview   11 HDFC Securities
Oct-18 Analysis of related party transactions   9 Edelweiss Securities
Oct-18 DTAB report puts more risk on the 900+ non-reviewed FDCs   14 Emkay Research
Oct-18 Muted Performance on the Cards   8 Reliance Securities Ltd.
Oct-18 Tough base on GST restocking to offset forex tailwinds   18 Edelweiss Securities
Oct-18 Prescription Charts of Interest – September 2018   13 Nirmal Bang
Sep-18 Key takeaways from Hyderabad pharma visits   33 Emkay Research
Sep-18 Healthcare Services industry in India   20 CARE Research
Sep-18 FDC ban impact expected, but government¿s follow-up measures pivotal   8 Emkay Research
Sep-18 China pharma: Breaking down the ¿Great Wall¿   8 Edelweiss Securities
Sep-18 E-pharmacies - Why they matter?   11 Emkay Research
Jul-18 Source of sustainable cash generation   15 IIFL
Jul-18 Volumes drive IPM growth; prices remain muted   22 Motilal Oswal
Jul-18 Trump forces Pfizer to defer price hike; but for how long?   12 Emkay Research
Jul-18 1QFY19 Results Preview   10 HDFC Securities
Jul-18 Bumper quarter on a favourable base   10 Edelweiss Securities
Jul-18 GST-dented base, FX to lift Q1FY19 earnings   12 Edelweiss Securities
Jun-18 Competition more potent than price control...   14 IIFL
Jun-18 US generic price erosion not coming off...   11 IIFL
Jun-18 Generic racks at pharmacies...   11 Emkay Research
Jun-18 Comeback on the cards¿   10 HDFC Securities
Jun-18 Volumes healthy, but price pressure evident   22 Motilal Oswal
Jun-18 Healthcare reforms ¿ Big will become bigger   7 Edelweiss Securities
Jun-18 Proposal for Pharma Index linked...   12 Emkay Research
Jun-18 Growth Pressure To Ease For Indian Generic Players In the US   10 Nirmal Bang
Jun-18 Small impact on specific companies if trade generics margins are capped   6 IIFL
May-18 Trump scheduled speech on Pharma...   12 Emkay Research
May-18 Strong deal flow in Emerging Market generics   5 IIFL
Apr-18 Higher volumes continue supporting IPM growth   22 Motilal Oswal
Apr-18 Mylan - a case study for Indian pharma   14 Edelweiss Securities
Apr-18 Time to refocus, should one look at premium valuations for safety?   86 IDBI Capital
Apr-18 4QFY18 Results Preview   10 HDFC Securities
Apr-18 Prescription Charts of Interest ¿ 4QFY18   11 Nirmal Bang
Apr-18 Tough times to continue   14 Edelweiss Securities
Mar-18 A deep-dive into what drives profitability   18 Edelweiss Securities
Mar-18 Heading into another year of record approvals   11 IIFL
Mar-18 Cost focus unlikely to solve growth issues   12 IIFL
Mar-18 Price decline impedes IPM growth   22 Motilal Oswal
Mar-18 Radiation oncology - Supply growing at 3X demand   10 Edelweiss Securities
Feb-18 Rising competition to put pressure in the near-term   16 Edelweiss Securities
Feb-18 First step towards Universal Healthcare   5 Edelweiss Securities
Feb-18 Giant awakens, makes its first move   6 Edelweiss Securities
Jan-18 Pharmaceuticals - 3QFY18 Results Preview   10 HDFC Securities
Jan-18 Weak US, INR appreciation to drag earnings   15 Edelweiss Securities